Physician profile
Jonathan Y Poon
NPI 1841340437
$19,423.56
in general payments reported to CMS, 2019-2025
53 companies · $7,667 in 2025
The $7,667 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,613 · 2020: $1,339 · 2021: $2,460 · 2022: $2,047 · 2023: $2,008 · 2024: $2,289 · 2025: $7,667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,458 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $3,930 · Travel and Lodging: $1,577.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,457.57 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $3,929.50 |
| Travel and Lodging | $1,576.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $5,766.22 | 2021-2025 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Novo Nordisk INC | $1,622.35 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $1,186.29 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,023.21 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $870.75 | 2019-2025 | Jardiance, Ofev |
| Boston Scientific Corporation | $751.78 | 2021 | |
| Lilly USA, LLC | $649.59 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Otsuka America Pharmaceutical, INC. | $636.96 | 2022-2025 | Rexulti, Abilify Maintena |
| Pfizer INC. | $552.34 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $507.67 | 2021-2025 | |
| Glaxosmithkline, LLC. | $489.39 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Shield Therapeutics INC | $467.17 | 2023-2025 | Accrufer |
| Sanofi-Aventis U.S. LLC | $435.73 | 2019-2025 | |
| Teva Pharmaceuticals USA, INC. | $411.66 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $400.09 | 2019-2024 | Xifaxan |
Show all 53 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Poon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.